The combination of midostaurin and selinexor revealed mild synergy commensurate to a minimal dose–response effect to midostaurin; whereas stronger synergy was evident in the combination of gilteritinib and selinexor with a corresponding higher dose response to gilteritinib toward FLT3-ITD AML (Figure S4d). The gene discussed is FLT3; the disease is acute myeloid leukemia.